InflaRx
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.About IFRX
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.
CEONiels Christoph Riedemann
CEONiels Christoph Riedemann
Employees74
Employees74
HeadquartersJena, Thueringen
HeadquartersJena, Thueringen
Founded2007
Founded2007
Employees74
Employees74
IFRX Key Statistics
Market cap67.20M
Market cap67.20M
Price-Earnings ratio-0.95
Price-Earnings ratio-0.95
Dividend yield—
Dividend yield—
Average volume610.12K
Average volume610.12K
High today$1.02
High today$1.02
Low today$0.9581
Low today$0.9581
Open price$0.99
Open price$0.99
Volume320.92K
Volume320.92K
52 Week high$2.77
52 Week high$2.77
52 Week low$0.7113
52 Week low$0.7113
Stock Snapshot
With a market cap of 67.2M, InflaRx(IFRX) trades at $1.01. The stock has a price-to-earnings ratio of -0.95.
During the trading session on 2026-01-22, InflaRx(IFRX) shares reached a daily high of $1.02 and a low of $0.96. At a current price of $1.01, the stock is +5.4% higher than the low and still -0.8% under the high.
Trading volume for InflaRx(IFRX) stock has reached 320.92K, versus its average volume of 610.12K.
Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.77 and a low of $0.71.
Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.77 and a low of $0.71.
Analyst ratings
75%
of 8 ratingsBuy
75%
Hold
25%
Sell
0%
People also own
Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.